Gedeon Richter announces transfer of oral contraceptive range from Consilient Health

Gedeon Richter announces transfer of oral contraceptive range from Consilient Health

London, United Kingdom, 14 June 2023 – Gedeon Richter UK Ltd. (“Gedeon Richter”) today announced that full marketing and distribution rights to an oral contraceptive range of branded generics, acquired from Consilient Health, have been transferred to the company. Under the terms of the transfer, Gedeon Richter has become the Marketing Authorisation holder in the UK for all the products within the range.

The branded generics portfolio includes seven combined oral contraceptives and one progestogen-only pill:

Combined oral contraceptives containing 30μg ethinylestradiol

• GEDAREL 30/150 - 30μg ethinylestradiol / 150μg desogestrel
• LUCETTE - 0.03mg ethinylestradiol / 3mg drospirenone
• MILLINETTE 30/75 - 30μg ethinylestradiol / 75μg gestodene
• RIGEVIDON - 30μg ethinylestradiol / 150μg levonorgestrel
• TRIREGOL - ethinylestradiol 30 / 40 / 30μg /levonorgestrel 50 / 75 / 125μg

Combined oral contraceptives containing 20μg ethinylestradiol

• GEDAREL 20/150 - 20μg ethinylestradiol / 150μg desogestrel
• MILLINETTE 20/75 - 20μg ethinylestradiol / 75μg gestodene

Progestogen-only pill

• CERELLE - 75μg desogestrel

“Our mission is to provide high-quality products at affordable prices,” said Tamas Neubauer, Managing Director UK and Ireland, Gedeon Richter. “The UK is experiencing a period of austerity post-pandemic, with the government looking to rein in spending across the health care system. The addition of eight branded generics to our oral contraception offering reinforces our position as a leader in family planning solutions, and partner to the NHS in helping achieve cost-savings – without compromising the ability of women to plan pregnancy around their lives.”

The deal is a good strategic fit for Gedeon Richter, bringing meaningful expansion to the company’s oral contraception franchise. The newly transferred products are the first and only branded generics in the company’s oral contraceptive range, extending its portfolio of oral contraceptives beyond innovative, high value-add branded originators. The transfer follows a trend Gedeon Richter has adopted across its family planning solutions more broadly, whereby the company is providing branded or hybrid generics of other methods such as the intrauterine system (IUS), alongside branded originators.        

As part of the transfer, Gedeon Richter has committed to continuing support for healthcare professionals with educational content about the products, as well as to providing information to UK women who have been prescribed one of the branded oral contraceptives in the range. 

“We have years of experience supporting women’s reproductive health and we are pleased to have branded generics as part of our oral contraceptive range for the first time,” said David Jordan, Medical Director UK and Ireland, Gedeon Richter. “Choice plays an important role when selecting a suitable contraceptive. We’re proud to provide multiple options at different price points to the NHS, with a view to ensuring women can choose a contraceptive method that’s right for them, and have the confidence it will be available in the UK long-term.” 

In England between 2017-2018, more than 3.1 million women who received contraception from the GP or pharmacies took either the combined pill or progestogen-only pill. 

The cash purchase price amounts to £32.5million.